What is the preferred antidepressant and its dosing for an adult male patient with anxiety, panic attacks, and nocturnal enuresis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Preferred Antidepressant for Adult Male with Anxiety, Panic Attacks, and Nocturnal Enuresis

For an adult male with anxiety, panic attacks, and nocturnal enuresis, imipramine is the preferred antidepressant at a starting dose of 25-50 mg at bedtime, titrated up to 150 mg/day as needed, as it uniquely addresses both conditions simultaneously.

Rationale for Imipramine Selection

The clinical scenario presents a unique dual indication where imipramine stands out as the only medication with established efficacy for both panic disorder/anxiety AND nocturnal enuresis in adults. While SSRIs are generally first-line for anxiety and panic attacks, they provide no benefit for enuresis—and in fact, recent evidence suggests fluoxetine is non-inferior to desmopressin for enuresis treatment 1, though this remains investigational.

Dosing Strategy

Starting dose: 25 mg at bedtime (can start at 50 mg if panic symptoms are severe) 2

Titration: Increase by 25 mg every 3-7 days as tolerated 3

Target dose for enuresis: 25-50 mg at bedtime (lower than antidepressant dosing) 4, 2

Maximum dose: 150 mg/day for combined indication 5

Expected response timeline:

  • Enuresis improvement: Within 1 month 2
  • Panic/anxiety improvement: 2-4 weeks (faster than typical antidepressant response) 2

Critical Safety Considerations

Mandatory pre-treatment screening:

  • Obtain baseline ECG to exclude underlying cardiac conduction abnormalities or long QT syndrome 2
  • Screen for personal history of palpitations, syncope, or family history of sudden cardiac death 4
  • Periodic ECG monitoring during treatment 2

Cardiac toxicity concerns: Imipramine carries risk of fatal cardiac arrhythmias, particularly in overdose 4, 2. This is the primary reason it has fallen to second/third-line status for enuresis in children, but remains relevant for adults when dual indication exists.

Common side effects: Anticholinergic effects (dry mouth, constipation), mood changes, nausea, insomnia 4, 6. These often appear before therapeutic benefits but may diminish with continued treatment 4.

Treatment Duration and Monitoring

  • Continue for 4-6 months if effective 2
  • For enuresis: Taper to lowest effective dose with drug holidays every 3 months to prevent tolerance 4
  • Monitor for both panic attack frequency and wet nights per week
  • Serum levels only indicated if no response at 2.5 mg/kg/day 2

Alternative Approach: SSRI Plus Separate Enuresis Treatment

If cardiac risk factors exist or imipramine is contraindicated, consider:

For panic/anxiety: Sertraline 25-50 mg daily, titrated to 150-200 mg/day 7, 8

  • Better tolerated than paroxetine with less weight gain and easier discontinuation 8
  • Equivalent efficacy to paroxetine for panic disorder 8
  • Less drug-drug interaction potential than other SSRIs 9

For enuresis (separate treatment): Desmopressin 0.2-0.6 mg orally at bedtime 2

  • Start with 0.2 mg (one tablet), increase to 2-3 tablets if needed
  • Monitor for hyponatremia/water intoxication (rare but serious) 2
  • Check electrolytes if intercurrent illness develops 2
  • Success rate 10-65%, but relapse rate up to 80% 2

Why Not Other SSRIs for Dual Purpose?

While fluoxetine showed non-inferiority to desmopressin for enuresis in one 2025 trial 1, this represents emerging evidence in a pediatric population and lacks sufficient adult data or guideline support. Fluoxetine and other SSRIs remain excellent for panic disorder 10, 11, 12 but require separate enuresis management.

Common Pitfalls to Avoid

  1. Underdosing imipramine: The anti-enuretic effect occurs at lower doses (25-50 mg) than antidepressant effects, but panic disorder may require higher dosing (up to 150 mg) 5, 2

  2. Skipping cardiac screening: This is non-negotiable given cardiotoxicity risk 2

  3. Premature discontinuation: Both conditions require 4-6 months of treatment; enuresis has 50% relapse rate with early cessation 2

  4. Ignoring fluid restriction with desmopressin: If using desmopressin, restrict evening/nighttime fluids to prevent hyponatremia 4, 2

  5. Overlooking behavioral interventions: Urotherapy, bladder training, and alarm therapy should accompany pharmacotherapy for enuresis 4, 2

Clinical Algorithm

Step 1: Obtain ECG and cardiac history screening

Step 2: If cardiac screening normal → Start imipramine 25 mg at bedtime

Step 3: Titrate by 25 mg every 3-7 days based on response and tolerability

Step 4: Target 50-150 mg/day depending on symptom control

Step 5: If cardiac contraindications exist → Sertraline 25-50 mg daily for panic/anxiety PLUS desmopressin 0.2 mg for enuresis

Step 6: Monitor panic attack frequency, wet nights, and side effects every 2-4 weeks initially

4, 2

References

Guideline

practice parameter for the assessment and treatment of children and adolescents with enuresis.

Journal of the American Academy of Child and Adolescent Psychiatry, 2004

Guideline

position paper for the treatment of nightmare disorder in adults: an american academy of sleep medicine position paper.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Research

Clomipramine and fluoxetine effects in the treatment of panic disorder.

Bosnian journal of basic medical sciences, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.